EP 0503055 A1 19920916 - INHIBITOR OF LYMPHOCYTE RESPONSE AND IMMUNE-RELATED DISEASE.
Title (en)
INHIBITOR OF LYMPHOCYTE RESPONSE AND IMMUNE-RELATED DISEASE.
Title (de)
INHIBITOR DER LYMPHOZYTEN-ANTWORT UND IMMUNVERWANDTER KRANKHEITEN.
Title (fr)
INHIBITEURS DE LA REPONSE DE LYMPHOCYTES ET DE MALADIES IMMUNITAIRES.
Publication
Application
Priority
US 57850690 A 19900906
Abstract (en)
[origin: WO9204049A1] Peptides having at least seven amino acids, preferably up to 20 amino acids, and most preferably 7 to 9 amino acids, comprising an amino acid sequence which corresponds to positions 180-186 of the Mycobacterium tuberculosis protein hsp 65 having the formula TFGLQLE, but differing therefrom by one to three amino acid substitutions in the positions 181-183, are disclosed. These peptides inhibit antigen recognition by T lymphocytes, such as recognition of hsp 65, and are capable of protecting a subject from an immune-related disease, such as autoimmune arthritis and to prevent rejection of a transplanted organ or tissue. Single amino acid substitutions, in particular with alanine, at positions corresponding to hsp 65 positions 183 and 181 are preferred. T cell lines specific for the above peptides and their use in treating or preventing immune-related disease is also disclosed.
Abstract (fr)
Peptides ayant au moins sept aminoacides, de préférence jusqu'à 20 aminoacides, idéalement de 7 à 9 aminoacides, comprenant une séquence d'aminoacides qui correspond aux positions 180-186 de la protéine Mycobacterium tuberculosis 65 du choc thermique (hsp) de la formule TFGLQLE, mais différant de celles-ci par une à trois substitutions d'aminoacides aux positions 181-183. Ces peptides inhibent la reconnaissance d'antigènes par des lymphocytes T, telle que la reconnaissance de la protéine hsp 65; elles peuvent protéger un sujet contre une maladie immunitaire, telle que l'arthrite auto-immune et prévenir le rejet d'organes ou de tissus greffés. On préfère les substitutions d'aminoacides simples, en particulier avec l'alanine, aux positions correspondant aux positions 183 et 181 de la hsp 65. On décrit aussi des lignées de lymphocytes T spécifiques aux peptides susmentionnés et leur utilisation dans le traitement et la prévention de maladies immunitaires.
IPC 1-7
A61K 37/02; A61K 39/00; C07K 3/00; C07K 7/06; C07K 7/08; C12N 5/08
IPC 8 full level
A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 39/04 (2006.01); A61P 37/00 (2006.01); A61P 37/06 (2006.01); C07K 14/00 (2006.01); C07K 14/35 (2006.01); C07K 14/47 (2006.01)
CPC (source: EP)
A61P 37/00 (2017.12); A61P 37/06 (2017.12); C07K 14/35 (2013.01); C07K 14/4703 (2013.01); A61K 38/00 (2013.01)
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IT LI LU NL SE
DOCDB simple family (publication)
WO 9204049 A1 19920319; AU 650065 B2 19940609; AU 8755991 A 19920330; CA 2071896 A1 19920307; EP 0503055 A1 19920916; EP 0503055 A4 19940216; IL 99429 A0 19920818; JP H05507501 A 19931028; NZ 239699 A 19931125; ZA 917097 B 19920930
DOCDB simple family (application)
US 9106434 W 19910905; AU 8755991 A 19910905; CA 2071896 A 19910905; EP 91918631 A 19910905; IL 9942991 A 19910906; JP 51784991 A 19910905; NZ 23969991 A 19910906; ZA 917097 A 19910906